Stock ticker :
NASDAQ
GILD
AS OF
Jan 14, closing price
Price
$71.77
Change
-$0.11 (-0.15%)
Capitalization
$90b
GILD
Stock ticker :
NASDAQ
22 days until earnings call
Intraday data for
Jan 14, closing price
Price
$71.77
Change
-$0.11 (-0.15%)
Capitalization
$90b

(GILD) Stock Forecast and AI Recommendations

a developer of therapeutic products and treatments for life threatening diseases
Industry PharmaceuticalsMajor

Gilead Sciences (GILD) Stock Stock Prediciton and Price Targets

Stock market charts, price targets, analyst ratings and a financial calendar
a developer of therapeutic products and treatments for life threatening diseases
Industry PharmaceuticalsMajor
A.I.dvisor published
a Summary for GILD with price predictions.
4:00 PM EST Jan 14

GILD sees its Stochastic Oscillator climbs out of oversold territory

On January 11, 2022, the Stochastic Indicator for GILD moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In 31 of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over 53%.

Stock Forecast, Price, News, Quote

Current price $71.77 crossed the resistance line at $70.63 and is trading between $74.26 support and $70.63 resistance lines. Throughout the month of 12/14/21 - 01/14/22, the price experienced a +2% Uptrend. During the week of 01/07/22 - 01/14/22, the stock enjoyed a +0.72% Uptrend growth.

Technical Analysis (Indicators)
Bullish Trend Analysis

Following a +1.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 144 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 47%.

The Aroon Indicator entered an Uptrend today. In 101 of 197 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 51%.

Bearish Trend Analysis

The 10-day RSI Indicator for GILD moved out of overbought territory on December 31, 2021. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 11 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 52%.

The Momentum Indicator moved below the 0 level on January 06, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on GILD as a result. In 71 of 113 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.

The Moving Average Convergence Divergence Histogram (MACD) for GILD turned negative on January 03, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 20 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 38%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.

GILD broke above its upper Bollinger Band on December 14, 2021. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.193) is normal, around the industry mean (5.061). P/E Ratio (12.225) is within average values for comparable stocks, (30.303). GILD's Projected Growth (PEG Ratio) (0.533) is slightly lower than the industry average of (2.433). GILD has a moderately high Dividend Yield (0.040) as compared to the industry average of (0.025). P/S Ratio (3.308) is also within normal values, averaging (4.595).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 49 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 62 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock slightly worse than average.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.dvisor published
Gilead Sciences Earnings Data

GILD is expected to report earnings to fall 42.64% to $1.52 per share on February 08

Gilead Sciences GILD Stock Earnings Report
Q4'21
Est.
$1.52
Q3'21
Beat
by $0.89
Q2'21
Beat
by $0.13
Q1'21
Met
by $2.08
Q4'20
Beat
by $0.15
The last earnings report on October 28 showed earnings per share of $2.65, beating the estimate of $1.76. With 8.32M shares outstanding, the current market capitalization sits at 90.03B.
A.I.dvisor found
Gilead Sciences Dividends
GILD paid dividends on December 30, 2021
Gilead Sciences GILD Stock Dividends
А dividend of $0.71 per share was paid with a record date of December 30, 2021, and an ex-dividend date of December 14, 2021. The ex-dividend date is usually set several business days before the record date. If a stock is purchased on its ex-dividend date or after, the next dividend payment will not be received. Instead, the dividends are repossessed by to the seller. If the stocks are purchased before the ex-dividend date, the buyer will receive the dividends.
A.I.dvisor
published General Information

General Information

Profile
Fundamentals
Details
Industry Biotechnology
Address 333 Lakeside Drive, Foster, CA, 94404
Phone +1 650 574-3000
Employees 13600
Web https://www.gilead.com
GILD

Select Stock attributes to show

Capitalization 90B
P/E Ratio 12.22
Risk (Beta) 0.06
Dividend Yield 0.04
Total Cash 5.738B
Total Cash/Share 4.57
Total Debt 27.7B
Total Debt/Equity 71.31
Projected Growth (PEG Ratio) 0.53
Revenue/Share (as % of the share price) 22%
Revenue 27.5B
ROE N/A
Book Value 21.5B
P/B Ratio 4.19
Cash Flow N/A
Earnings 5.890
Average Daily Volume YTD N/A
Common Shares Outstanding - Security Level 1M
Current Ratio 1.37
Current Revenue Per Employee 545,661.75
Dividends Per Share - Security 0.71
EBITDA 12.3B
Float N/A
Float - Current N/A
Gross Income Margin 83.52
Revenue To Assets 11.56
Shares Held By Institutions 769B
Shares Outstanding - Current N/A
Total Liabilities 45.6B
Total Volume MTD N/A
Value Over
Gain YTD -1.157
Group Domestic Stock Funds
Category Pharmaceuticals
Total Expense Ratio
Min. Initial Investment 0.00 USD
Fund Existence
Turnover
Front Load
Net Assets 0.00 USD
Manager Tenure
Group Domestic Stock Funds
Category Pharmaceuticals
Capitalization 90.03b USD
P/E Ratio 12.224939
Total Cash 5.74b USD
Projected Growth 0.53
Total Debt 27.69b USD
Revenue 27.48b USD
Risk (Beta) 0.06
Dividend Yield 0.04
Total Cash/Share 4.57
Total Debt/Equity 71.31
Revenue/Share 22.00USD as % of share price
Group Domestic Stock Funds
Category Pharmaceuticals
Net Assets 0.00 USD
Fund Existence
Turnover
Capitalization
Yield
Total Expense Ratio
Investment Style
Risk (Beta)
Group Domestic Stock Funds
Category Pharmaceuticals
Market Capitalization 0.00 USD
Volume 0.00 USD